Tumor immunogenomic signatures improve a prognostic model of melanoma survival

Abstract Background Tumor mutation burden (TMB) has been associated with melanoma immunotherapy (IT) outcomes, including survival. We explored whether combining TMB with immunogenomic signatures recently identified by The Cancer Genome Atlas (TCGA) can refine melanoma prognostic models of overall su...

Full description

Bibliographic Details
Main Authors: Leah Morales, Danny Simpson, Robert Ferguson, John Cadley, Eduardo Esteva, Kelsey Monson, Vylyny Chat, Carlos Martinez, Jeffrey Weber, Iman Osman, Tomas Kirchhoff
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Journal of Translational Medicine
Subjects:
Online Access:https://doi.org/10.1186/s12967-021-02738-0